GenIP has issued a bullish commercial update, pointing to continued order flow across the US, Asia and other key markets as it heads into 2026 on the back of around 330% revenue growth in FY25.
Asia has been a major strength for the group, growing by roughly 3,500% year on year and now accounting for the largest share of the company’s revenue.
Europe and Latin America also contributed meaningfully, up around 111% and 51% respectively, though from smaller bases.
There were no revenue figures in today’s update, but the announcement pointed towards growth in key offerings.
The technology commercialisation platform says client demand is shifting towards larger, multi-year engagements at the portfolio level rather than one-off technology evaluations. The company believes this trend should support both revenue visibility and deal sizes going forward.
Renewal conversations with FY25 clients are said to be progressing well, with several looking to expand their scope, consistent with the company’s reported 90% retention rate. This should see revenues grow again in the current financial year.
On the product side, GenIP said Invention Prioritizer is now in active use with several clients, including Brazil’s National Nuclear Energy Commission, while Invention Validator is completing its first deployment at a South African research university, carrying an expected 60% gross margin.
GenIP has also been building out its commercial team, bringing in a global enterprise sales lead to tap its previously largely unexplored corporate market, alongside a Latin America specialist with WIPO advisory credentials and a further Asia hire in the pipeline.
With its largest market still accelerating and a growing institutional pipeline at advanced stages across multiple regions, GenIP appears poised to build momentum as we move through 2026.
“GenIP is delivering strong progress across all of our strategic priorities. Asia’s exceptional growth, Europe’s accelerating momentum and the long-term potential we see in Latin America demonstrate the global demand for our platform and products,” said Melissa Cruz, Chief Executive Officer of GenIP.
“Clients are deepening their engagement with us, adopting our broader product suite and increasingly seeking portfolio-level insight. With a growing pipeline, strong renewal activity and a clear strategic focus, GenIP is well positioned for its next phase of growth.”
GenIP shares were hit last after the company conducted a heavily discounted placing. Since then, shares have built a base around 9p – 10p and now have a market cap of less than £2m.